Presentations, Interviews & Media

16-Jul-2026	Hudson Institute partnership video with Dr Olivier Laczka

12-Jun-2026	CEO Dr Olivier Laczka interview with Proactive Investors

22-May-2026	Sofra technology draws global interest as CSL to present vaccine delivery data

22-Apr-2026	Noxopharm flags prolonged skin retention data for SOF-SKN as it moves toward human trial

21-Apr-2026	Noxopharm appoints Dr Olivier Laczka as Chief Executive Officer \| BioMelbourne Network

13-Feb-2026	Noxopharm says paper reveals science behind its immune system platform

10-Feb-2026	Tiny one- to three-base RNAs could help stop autoimmune inflammation, study suggests

10-Feb-2026	Tiny RNA fragments unlock massive autoimmune treatment potential - Hudson Institute of Medical Research

18-Nov-2025	Noxopharm 2025 AGM Corporate Presentation

29-Oct-2025	World-first RNA trial a breakthrough for lupus patients

17-Sep-2025	Stockhead interview - Noxopharm has the ‘burning fire’ of inflammation squarely in its sights

28-Aug-2025	Sofra technology platform presentation

29-May-2025	Ausbiz interview - The small cap tackling inflammatory disease

19-Nov-2024	Noxopharm 2024 AGM Corporate Presentation

3-Sep-2024	Ausbiz interview on brain cancer research

20-Aug-2024	Proactive Investors interview: First trial for SOF-SKN™

19-Aug-2024	Ausbiz interview on HERACLES trial

14-Jun-2024	Chief Executive Officer Letter

16-Nov-2023	Noxopharm 2023 AGM Corporate Presentation

16-Oct-2023	Noxopharm talks partnership with Hudson Institute of Medical Research

22-May-2023	Noxopharm hails new Sofra™ drug inflammation results

17-Nov-2022	Noxopharm 2022 AGM Corporate Presentation

4-Oct-2022	Ausbiz interview regarding pancreatic cancer research

14-Sep-2022	Noxopharm reveals encouraging new pancreatic cancer preclinical study data

7-Jun-2022	Noxopharm New Corporate Presentation June 2022

Copyright © Noxopharm Limited (ASX:NOX)